Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Pro Tip From VIVA: Plan and prep your meals ahead of time to ensure you have nutritious options available
Buyers may also review our category page for Weight Loss injection procurement planning
In 2005, the Food and Drug Administration (FDA) approved exenatide (Byetta), the first glucagon-like peptide-1 ( GLP-1 ) receptor agonist, which was designed to help lower blood glucose levels (blood sugar)in people with type 2 diabetes
A controlled clinical study
Tirzepatide is a dual-agonist medication that activates both GLP-1 and GIP receptors , amplifying appetite regulation and glucose control
People already seeing results from injections appear more likely to trust the treatment format they already know
